10x Genomics (TXG) Expected to Announce Quarterly Earnings on Thursday

10x Genomics (NASDAQ:TXG) is projected to announce its earnings results after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. 10x Genomics has set its FY 2025 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

10x Genomics (NASDAQ:TXG) last released its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Price Performance

Shares of TXG opened at $12.07 on Wednesday. The business’s fifty day moving average price is $14.52 and its 200 day moving average price is $17.22. 10x Genomics has a 12-month low of $10.80 and a 12-month high of $48.42. The stock has a market capitalization of $1.46 billion, a PE ratio of -7.89 and a beta of 1.85.

Analysts Set New Price Targets

TXG has been the topic of several research analyst reports. Stifel Nicolaus reduced their price objective on 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Leerink Partnrs lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. lowered their price target on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Barclays lowered their price target on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Finally, Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $25.00 to $12.00 in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $20.57.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.